Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “interleukin”

134 pharma patents match "interleukin" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 134
Index total 30,257
Page 3 / 6

Quick answer

This filtered view shows 134 pharmaceutical patents matching "interleukin" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

134 results for “interleukin” · 30,257 patents in full index Clear search

  1. US 10851158

    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted

  2. US 10787490

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted

  3. US 10781242

    Interleukin-2 fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted

  4. US 10774141

    Antibody for binding to interleukin 4 receptor

    SuZhou Connect Biopharmaceuticals, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted

  5. US 10738112

    Anti-human interleukin-17A monoclonal antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted

  6. US 10696724

    Activatable interleukin-2 polypeptides

    Werewolf Therapeutics, Inc. · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted

  7. US 10696723

    Activatable interleukin 12 polypeptides

    Werewolf Therapeutics, Inc. · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted

  8. US 10611845

    Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

  9. US 10435473

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  10. US 10196424

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted

  11. US 10166288

    Vaccines having an antigen and interleukin-21 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted

  12. US 10130705

    Vaccines with interleukin-33 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted

  13. US 10106592

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted

  14. US 10093708

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  15. US 10072086

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted

  16. US 10035824

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted

  17. US 10023614

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  18. US 10005834

    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted

  19. US 9840558

    Human antibody specific for interleukin-1alpha

    XBIOTECH INC. · Granted Dec 12, 2017 · Expires Dec 7, 2037

    granted

  20. US 9669091

    Vaccines having an antigen and interleukin-23 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted

  21. US 9624268

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted

  22. US 9487590

    Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Nov 8, 2016 · Expires Nov 3, 2036

    granted

  23. US 9475839

    Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted

  24. US 9339528

    Methods for treating epithelium trauma of the intestinal mucosa using interleukin-1 receptor antagonist

    GENERAL REGENERATIVES, LTD. · Granted May 17, 2016 · Expires May 12, 2036

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.